LDXHF.US Lumos Diagnostics Holdings Limited
- Market cap
- USD 49.4M
- P/E
- -
- P/B
- 2.16x
- ROE
- -22.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is LDXHF.US undervalued?
Graham numberThe Graham number of Lumos Diagnostics Holdings Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lumos Diagnostics Holdings Limited fundamental analysis
No fundamental analysis for Lumos Diagnostics Holdings Limited yet.
Lumos Diagnostics Holdings Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lumos Diagnostics Holdings Limited
Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is he…
Full company profileLumos Diagnostics Holdings Limited financial statements
Lumos Diagnostics Holdings Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 1.92M | 4.48M | 5.78M | 19.0M | 11.6M | 10.5M | 11.1M | 12.5M | 13.5M |
| Gross Profit | 838K | 2.04M | 2.51M | 638K | 4.46M | -4.28M | 7.10M | 7.91M | -7.90M |
| Operating Income | -1.35M | -2.94M | -10.7M | -11.1M | -23.9M | -6.56M | -7.12M | -7.84M | -14.4M |
| EBITDA | -1.20M | -2.41M | -8.24M | -10.5M | -40.2M | -2.84M | -5.39M | -4.60M | -11.8M |
| Net Income | -1.26M | -4.59M | -9.26M | -15.1M | -45.7M | -8.88M | -8.59M | -7.18M | -5.06M |
| EPS | -0.01 | -0.03 | -0.05 | -0.09 | -0.30 | -0.04 | -0.02 | -0.01 | -0.01 |
| Balance Sheet | |||||||||
| Total Assets | 8.88M | 25.4M | 30.2M | 98.0M | 36.9M | 25.4M | 26.8M | 20.8M | 40.7M |
| Total Liabilities | 5.90M | 13.7M | 8.10M | 39.7M | 19.1M | 15.9M | 19.7M | 14.7M | 17.9M |
| Shareholders' Equity | 2.98M | 11.7M | 22.1M | 58.3M | 17.9M | 9.50M | 7.11M | 6.16M | 22.8M |
| Cash & Short-term Investments | 243K | 3.07M | 850K | 44.9M | 7.98M | 3.02M | 6.48M | 1.96M | 15.4M |
| Total Debt | 5.12M | 10.4M | 4.10M | 7.96M | 7.19M | 9.79M | 8.06M | 6.99M | 5.93M |
| Cash Flow | |||||||||
| Operating Cash Flow | -288K | -3.03M | -3.75M | -10.9M | -18.0M | -9.64M | 946K | -9.33M | 1.04M |
| Capital Expenditure | 1.68M | 2.53M | 6.50M | 5.88M | 4.36M | 153K | 98.0K | 53.0K | 2.59M |
| Free Cash Flow | -1.97M | -5.56M | -10.3M | -16.8M | -21.5M | -9.70M | 848K | -9.39M | -1.56M |
| Ratios | |||||||||
| ROE | -42.5% | -39.4% | -41.9% | -26.0% | -255.7% | -93.5% | -120.9% | -116.7% | -22.1% |
| ROA | -14.2% | -18.1% | -30.6% | -15.4% | -123.8% | -34.9% | -32.0% | -34.5% | -12.4% |
| Net Profit Margin | -66.0% | -102.6% | -160.2% | -79.7% | -393.2% | -84.3% | -77.2% | -57.5% | -37.5% |
| Debt to Equity | 1.72x | 0.89x | 0.19x | 0.14x | 0.40x | 1.03x | 1.13x | 1.13x | 0.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lumos Diagnostics Holdings Limited dividends
Lumos Diagnostics Holdings Limited has not paid dividends in the last 9 fiscal years.
Last stock split: 1077:1000 on Jul 11, 2022.
Who owns Lumos Diagnostics Holdings Limited
- Insiders 20.65%
- Institutions 19.41%
- Public & others 59.93%
- Shares outstanding 988M
- Free float 528M
Lumos Diagnostics Holdings Limited company profile
- Company name
- Lumos Diagnostics Holdings Limited
- Ticker
- LDXHF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 2724 Loker Ave West, Carlsbad, CA, United States, 92010
- Phone
- 855 586 6739
- Website
- lumosdiagnostics.com
About Lumos Diagnostics Holdings Limited
Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Lumos Diagnostics Holdings Limited management
9- Mr. Douglas WardCEO, MD & Director
- Mr. Barrie LambertChief Financial Officer
- Mr. Anthony FavaloroVice President of Quality & Operations
- Dr. Sacha Dopheide Ph.D.Chief Technology Officer
- Ms. Sarah GlubkaVice President of Human Resources
- Mr. Paul KaseChief Commercial Officer
- Ms. Tracy Weimar BA, MBACompany Secretary
- Ms. Annie BellVice President of Medical Affairs
- Amelia StephensGlobal Marketing and Awareness Consultant